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Abstract
Background: This work seeks to evaluate the association between the C/D ratios (plasma concentration of tacrolimus
divided by daily dose of tacrolimus per body weight) of tacrolimus and the haplotypes of MDR1 gene combined by C1236T
(rs1128503), G2677A/T (rs2032582) and C3435T (rs1045642), and to further determine the functional significance of
haplotypes in the clinical pharmacokinetics of oral tacrolimus in Han Chinese liver transplant recipients.
Methodology/Principal Findings: The tacrolimus blood concentrations were continuously recorded for one month after
initial administration, and the peripheral blood DNA from a total of 62 liver transplant recipients was extracted. Genotyping
of C1236T, G2677A/T and C3435T was performed, and SNP frequency, Hardy-Weinberg equilibrium, linkage disequilibrium,
haplotypes analysis and multiple testing were achieved by software PLINK. C/D ratios of different SNP groups or haplotype
groups were compared, with a p value,0.05 considered statistically significant. Linkage studies revealed that C1236T,
G2677A/T and C3435T are genetically associated with each other. Patients carrying T-T haplotype combined by C1236T and
G2677A/T, and an additional T/T homozygote at either position would require higher dose of tacrolimus. Tacrolimus C/D
ratios of liver transplant recipients varied significantly among different haplotype groups of MDR1 gene.
Conclusions: Our studies suggest that the genetic polymorphism could be used as a valuable molecular marker for the
prediction of tacrolimus C/D ratios of liver transplant recipients.
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Introduction
To lower the risk of rejection after allogenetic organ transplan-
tation, immunosuppressive drugs are widely used to reduce the
immune system activity. Tacrolimus, also named FK506, is a kind
of immunosuppressive drugs, and able to inhibit the multiplication
of T-cells [1]. Postoperative patients have to taketacrolimus all their
lives to make a better graft survival, which results in heavy financial
costs [1]. The optimal use of tacrolimus could not only lower the
financial cost but also reduce the side effects caused by tacrolimus,
which makes it a valuable therapy for liver transplant recipients.
However, pharmacokinetic characteristics of tacrolimus vary
dramatically among individuals. Pharmacokinetic characteristics
could be influenced in many ways, one of which may be the genetic
factors including single nucleotide polymorphism (SNP), haplotype
and DNA methylation [2,3,4,5,6].
Human multidrug resistance (MDR1) gene, also named P-
glycoprotein, is a member of the ATP-binding cassette superfam-
ily. MDR1 protein anchors in cell membrane, and acts as an efflux
transporter of various substrates for cell protection [4,6]. It has
been reported in the literature that tacrolimus is one substrate of
MDR1 [5,7,8]. MDR1 is polymorphic, and at least 50 SNPs have
been found so far [4,9,10,11,12,13]. The functional consequences
of reported SNPs are not completely understood and still
controversial to date. SNPs occur as a result of single-nucleotide
substitutions in coding region and non-coding region, which might
influence mRNA expression [14] and protein translation and
folding [6,8], and finally affect drug pharmacokinetic character-
istics. Moreover, the allelic frequency of MDR1 SNPs varies widely
among ethnic groups [4,5,6]. Haplotype is a set of genetically
associated SNPs [15,16,17], and can be mathematically calculated
by software including PLINK and Haploview [18,19]. Linkage
studies showed that there is strong linkage disequilibrium among
the highly frequent polymorphisms C1236T (rs1128503),
G2677A/T (rs2032582) and C3435T (rs1045642) [6,20,21].
Furthermore, the effects of haplotype on drug response and
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on specific mechanism have demonstrated that haplotypes may
alter mRNA stability [24], protein conformation and inhibitor
efficiency [6].
Dose-adjusted trough concentration (concentration/dose [C/
D], plasma concentration of drug divided by daily dose of drug per
body weight) was used as the criteria for comparison among
different SNP or haplotype groups in most of the previous studies
[25,26,27,28,29]. We have already observed lower tacrolimus C/
D ratios in liver transplant recipients of MDR1 C3435T C/C
homozygotes previously [28]. Our new findings not only
supported the previous observation, but also provided the evidence
that MDR1 haplotype could affect tacrolimus C/D ratios.
Methods
Patients
The population in this study was Han Chinese, including 5
female and 57 male, aged from 21 to 64 years old (46.669.3), and
weighed from 50 to 85 kg (66.468.4). For all the patients,
Table 1. Demographic characteristics of liver transplant patients.
SNP Genotype N Gender(M/F) Age (mean ± S.D.) Weight, kg (mean ± S.D.)
C1236T C/C 9 (14.5%) 9/0 47.969.5 69.368.4
C/T 25 (40.3%) 24/1 44.869.4 68.768.5
T/T 28 (45.1%) 24/4 47.969.1 63.467.5
G2677A/T A/A 2 (3.2%) 2/0 43.0611.3 65.569.2
A/G 8 (12.9%) 8/0 49.666.5 71.167.7
A/T 6 (9.7%) 5/1 40.0612.5 69.269.6
G/G 16 (25.8%) 15/1 48.466.4 63.168.7
G/T 22 (35.4%) 20/2 46.8610.8 67.067.9
T/T 8 (12.9%) 7/1 45.468.8 62.167.0
C3435T C/C 7 (11.3%) 6/1 46.668.8 60.766.2
C/T 24 (38.7%) 24/1 44.8610.8 66.368.0
T/T 31 (50%) 28/3 48.068.0 67.768.7
doi:10.1371/journal.pone.0025933.t001
Table 2. SNPs frequencies in liver transplant patients.
SNP position Alleles Frequency Genotypes Frequency Hardy–Weinberg equilibrium Comparison of C/D ratios
Allele N Genotype N O(HET)
d E(HET)
e p C/D ratios p
C1236T C 43 (34.7%) C/C 9 (14.5%) 0.4032 0.453 0.4048 143.50637.99 0.6772
T 81 (65.3%) C/T 25 (40.3%) 142.73639.23
T/T 28 (45.1%) 138.26647.61
G2677A/T(A-K)
a A 18 (14.5%) A/A 2 (3.2%) 0.2258 0.2482 0.5985 146.20635.66 0.4166
K 106 (85.5%) A/K 14 (22.6%) 139.01644.86
K/K 46 (74.2%) 152.23650.23
G2677A/T(T-R)
b T 44 (35.5%) T/T 8 (12.9%) 0.4516 0.4579 1 145.35641.76 0.2677
R 80 (64.5%) T/R 28 (45.2%) 141.73644.17
R/R 26 (41.9%) 122.77638.51
G2677A/T(G-W)
c G 62 (50.0%) G/G 16 (25.8%) 0.4839 0.5 0.8025 148.33645.48 0.5398
W 62 (50.0%) G/W 30 (48.4%) 137.76642.17
W/W 16 (25.8%) 138.82641.98
C3435T C 38 (30.6%) C/C 7 (11.3%) 0.3871 0.4251 0.5496 117.54623.16 0.0419
T 86 (69.4%) C/T 24 (38.7%) 137.95649.83
T/T 31 (50%) 150.20648.05
C/C 117.54623.16 0.0240
C/T+T/T 144.20640.05
athe character ‘K’ is for T, thymine, or G, guanine.
bthe character ‘R’ is for A, adenine, or G, guanine.
cthe character ‘W’ is for A, adenine, or T, thymine.
dO(HET) is short for observed heterozygosity.
eE(HET) is short for expected heterozygosity.
doi:10.1371/journal.pone.0025933.t002
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The oral administration of tacrolimus and steroid was introduced
in our previous study [28].
Ethics statement
The research protocol was approved by the Institutional Review
Board, Key Lab of Combined Multi-organ Transplantation,
Ministry of Public Health. Informed written consent was obtained
according to the Declaration of Helsinki.
Data Collection and Therapeutic Drug Monitoring
After the initial administration of tacrolimus, all patients
received clinical evaluations and laboratory tests in the first
month. The daily dose (mg) of tacrolimus was recorded, and the
weight-adjusted dosage (mg/kg/d) was calculated. Drug blood
levels were measured by immunoassay on the IMx analyzer
(Abbott Diagnostics Laboratories, Abbott-Park, IL). Dose-adjusted
trough concentrations were calculated by dividing tacrolimus
trough concentrations by the corresponding dose on an mg/kg
basis (concentration/dose [C/D] ratio).
Genotyping
Genomic DNA of patients was extracted from peripheral blood
using QIAamp DNA Blood mini kit (QIAGEN, Hilden, Germany)
following the manufacturer’s instruction. RFLP (restriction
fragment length polymorphism) PCR method was used to
genotype the position C1236T, G2677A/T and C3435T. Primer
pairs 59 TTCACTTCAGTTACCCATC 39 and 59 CATA-
GAGCCTCTGCATCA 39 and restriction enzyme BsuRI were
used to distinguish T allele from C allele of C1236T, with primer
pairs 59 AGAGCATAGTAAGCAGTAGGGAGTA 39 and 59
GCAAATCTTGGGACAGGAATA 39 and restriction enzyme
RsaI for distinguishing A allele from G or T allele of G2677A/T,
primer pairs 59 AGTAAGCAGTAGGGAGTAACA 39 and 59
GATAAGAAAGAACTAGAACGT 39 and restriction enzyme
AclI for distinguishing T allele from G or A allele of G2677A/T,
primer pairs 59 GATCTGTGAACTCTTGTTTTCA 39 and 59
GAAGAGAGACTTACATTAGGC 39 and restriction enzyme
MboI for distinguishing T allele from C allele of C3435T. PCR
and products digestion by restriction enzyme were performed as
reported [30].
Statistical Analysis
Nonparametric tests, including Mann-Whitney test and Krus-
kal-Wallis test, were applied to assess significance test for
comparisons of all group pairs, with a further confirmation by
multiple test, max(T) permutation by 10000 times. Nonparametric
tests were performed by Graphpad Prism 5.03 (Graphpad
Software, San Diego, CA, USA). Hardy-Weinberg equilibrium,
linkage disequilibrium, haplotype frequency analyses and max(T)
permutation were performed by PLINK v1.06 (http://pngu.mgh.
harvard.edu/purcell/plink/). The expectation-maximization (E-
M) algorithm was used to estimate haplotype frequencies by
PLINK. A p value,0.05 was considered statistically significant.
Results
Genotype Frequency of patients
All single SNP genotypes were recorded, and frequencies were
calculated. No statistical significance was found among genotype
groups related to gender, age and weight (Table 1). Results of
Kruskal-Wallis tests were not shown. As mentioned in method,
PLINK was used to analyze Hardy-Weinberg equilibrium, linkage
disequilibrium and haplotype frequencies. G2677A/T has 3
alleles, however, according to the user manual, PLINK is unable
to analyze SNPs with more than 2 alleles. Therefore, when one
allele was compared with other two alleles, there had to be a new
character to represent the two alleles. In accordance to the IUPAC
(Union of Pure and Applied Chemistry) coding standards, ‘K’ was
used as the abbreviation for T and G alleles, with ‘R’ for A and G
alleles together and ‘W’ for A and T alleles together. So G2677A/
T was also named as G2677A/T(A-K), G2677A/T(T-R) or
G2677A/T(G-W). All three SNPs frequencies were in accordance
with Hardy-Weinberg equilibrium, and the p value were .0.05
(Table 2).
Effect of SNPs on Tacrolimus Dose Requirement
Data of oral tacrolimus dose was collected, and the relationship
between MDR1 SNP genotypes and C/D ratio was investigated.
No statistically significant association was observed in position
C1236T and G2677A/T, except C3435T (Table 2). Similar to the
results of our previous study [28], we found that recipients with C/
C genotype at C3435T would require a little higher dose of
tacrolimus compared to those with C/T and T/T genotypes
(Table 2).
Table 3. Haplotype analysis of different pairs of the three
SNPs.
Combined SNPs Haplotypes N LD
a
C1236T vs G2677A/T(A-K) C-A 17 (13.5%) D9=0.897
T-A 1 (1%)
C-K 26 (21.1%)
T-K 80 (64.3%)
C1236T vs G2677A/T(T-R) C-T 4 (3.4%) D9=0.724
T-T 40 (32.1%)
C-R 39 (31.3%)
T-R 41 (33.2%)
C1236T vs G2677A/T(G-W) C-W 21 (17.3%) D9=0.000
T-W 41 (32.7%)
C-G 21 (17.3%)
T-G 41 (32.7%)
C1236T vs C3435T C-C 1 (1.1%) D9=0.895
T-C 37 (29.5%)
C-T 42 (33.6%)
T-T 44 (35.8%)
G2677A/T(A-K) vs C3435T A-C 0 (0%) D9=1.000
K-C 38 (30.6%)
A-T 18 (14.5%)
K-T 68 (54.8%)
G2677A/T(T-R) vs C3435T T-C 35 (28%) D9=0.868
R-C 3 (2.6%)
T-T 9 (7.4%)
R-T 77 (61.9%)
G2677A/T(G-W) vs C3435T W-C 34 (27.5%) D9=0.796
G-C 4 (3.1%)
W-T 28 (22.5%)
G-T 58 (46.9%)
aLD, linkage disequilibrium.
doi:10.1371/journal.pone.0025933.t003
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G2677A/T and C3435T, and association among the three SNPs,
also called haplotype, might influence drug pharmacokinetics. So
we tested the linkage disequilibrium of all pairs of these three SNPs
at the beginning. When C1236T combined with C3435T, or
G2677A/T combined with C3435T, linkage disequilibrium was
found (Table 3). C1236T also had linkage disequilibrium with
G2677A/T(A-K) and G2677A/T(T-R), not with G2677A/T(G-
W) (Table 3). And then according to the result of linkage
disequilibrium, haplotype frequency analyses were performed,
which do not include the combination between C1236T and
G2677A/T(G-W). The haplotypes of individuals were recorded.
No statistical significance was found in either of the 6 different
pairs of combination (Table 4). But when C1236T and G2677A/
T(T-R) were combined, patients with T-T/T-T, T-T/C-T and T-
T/T-R haplotypes showed lower C/D ratios than those with T-
R/T-R, T-R/C-R, T-T/C-R and C-R/C-R, which meant that
patients carrying T-T haplotype and with an additional T/T
homozygote at position C1236T or G2677A/T would require
higher dose of tacrolimus (Table 5). Furthermore, it seemed that
patients with T-C/T-C or T-C/R-T haplotypes showed lower C/
D ratios than those with other haplotypes, which meant patients
carrying T-C haplotype with the combination of G2677A/T(T-R)
and C3435T required higher dose of tacrolimus to maintain serum
concentration. However, after the max(T) permutation adjust-
ment, no statistical significance was observed (Table 5).
Discussion
It has been reported that there are more than 50 SNPs in
human MDR1 gene [9,10,11,12,13,31]. SNPs spread from the 59
start to the 39 untranslated region in MDR1 transcript, resulting in
both synonymous and non-synonymous mutations [4,5,6]. Three
SNPs, C1236T, G2677A/T and C3435T, all locate in exons.
Mutation of G2677A/T causes coding sequence missense, while
the others are synonymous [5]. Missense substitutions in amino
acid may result in abnormal protein folding, moreover, there has
been a hypothesis that the presence of rare codons, marked by
synonymous polymorphisms, may affect the insertion of MDR1
into the membrane and alter the structure of substrate interaction
sites [8]. These SNPs have become research focus, which include
effects of SNPs and haplotypes in different ethnic groups
[7,13,32,33,34,35,36,37,38] on MDR1 mRNA stabilization
[24,39,40,41] or protein expression and folding [5,10] in patients,
and effects on substrates efflux in cell models [5,8].
Table 4. Tacrolimus concentration/dose (C/D) ratios of different haplotype groups.
Combined SNPs Haplotypes N C/D Combined SNPs Haplotypes N C/D
C1236T - G2677A/T(A-K) C-A/C-A 1 (1.6%) 188.0760.00 G2677A/T(A-K) - C3435T A-T/A-T 2 (3.2%) 156.40643.84
C-A/T-K 9 (14.5%) 147.86644.63 A-T/K-C 4 (6.5%) 149.08629.46
C-K/C-A 5 (8.1%) 128.09640.17 K-T/A-T 10 (16.1%) 142.79635.38
C-K/C-K 3 (4.8%) 116.71640.46 K-T/K-T 19 (30.6%) 137.01641.89
T-A/C-A 1 (1.6%) 177.6160.00 K-T/K-C 20 (32.3%) 145.33649.36
T-K/C-K 15 (24.2%) 145.89647.77 K-C/K-C 7 (11.3%) 126.42638.70
T-K/T-K 28 (45.2%) 137.47639.28
C1236T - G2677AT-(T-R) C-R/C-R 8 (12.9%) 135.65641.19 G2677AT-(T-R) - C3435T R-T/R-T 23 (37.1%) 139.23636.19
C-R/C-T 1 (1.6%) 93.4460.00 R-T/R-C 3 (4.8%) 192.31646.51
C-R/T-T 12 (19.4%) 146.65641.54 R-T/T-T 7 (11.3%) 149.24649.34
T-R/C-R 11 (17.7%) 141.91644.64 T-T/T-T 1 (1.6%) 97.1760.00
T-R/T-R 7 (11.3%) 142.06630.32 T-C/R-T 21 (33.9%) 139.10642.89
T-R/T-T 15 (24.2%) 135.15638.28 T-C/T-C 7 (11.3%) 126.42638.70
T-T/C-T 2 (3.2%) 188.07662.59
T-T/T-T 6 (9.7%) 138.83653.93
C1236T - C3435T C-T/C-T 9 (14.5%) 130.97642.39 G2677A/T(G-W) - C3435T G-T/G-T 13 (21.0%) 138.18637.49
C-T/T-C 10 (16.1%) 147.61644.29 G-T/G-C 3 (4.8%) 192.31646.51
T-T/C-T 14 (22.6%) 148.35649.13 G-T/W-T 13 (21.0%) 138.66640.31
T-T/T-T 8 (12.9%) 137.06636.82 W-T/W-T 5 (8.1%) 149.00649.54
T-T/T-C 14 (22.6%) 137.15636.54 W-T/W-C 4 (6.5%) 149.08629.46
T-C/C-C 1 (1.6%) 143.8260.00 W-C/G-T 17 (27.4%) 137.04644.43
T-C/T-C 6 (9.7%) 138.83643.93 W-C/W-C 7 (11.3%) 126.42638.70
doi:10.1371/journal.pone.0025933.t004
Table 5. Statistical analysis of tacrolimus concentration/dose
(C/D) ratios at 1 month after drug initiation between
haplotype groups.
SNP position Haplotypes C/D p
C1236T - G2677A/
T(A-K)
T-T/T-T+T-T/C-T+T-T/T-R 128.65643.60 0.0156
T-R/T-R+T-R/C-R+T-T/C-R+C-R/C-R 148.14640.40 0.034#
G2677A/T(T-R) -
C3435T
T-C/T-C+T-C/R-T 132.45637.16 0.049
R-T/R-T+R-T/R-C+R-T/T-T 151.85639.23 0.098#
#indicated the p value given by max(T) permutation.
doi:10.1371/journal.pone.0025933.t005
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and C3435T have significant association with tacrolimus or
cyclosporine pharmacokinetics, and their clinical behaviors exhibit
significantly different requirements of drug dose among different
SNP groups. Recipients with C/C homozygotes of MDR1 in
position C3435T showed significantly lower dose-adjusted tacro-
limus concentrations compared with the other groups [28,37,42].
Since the ethnic population was Han Chinese, the same
population in our previous study [28], similar phenomenon was
observed. Some other research groups also identified SNPs related
to cyclosporine pharmacokinetics, still there are controversies. In
some cases, recipients with C/C homozygote in position C3435T
required higher dose of cyclosporine [43,44], while others did not
[45,46,47]. One of the explanations is that SNPs frequencies may
vary quite differently depending on specific ethnic groups, for
instance, homozygosity for T allele in position C1236T is 37.5%in
Japanese [48], while 13.3% in Caucasians [11]. Different ethnic
populations have different SNP frequencies at the same position,
which may cause the controversial results.
Genetic association of SNPs, named haplotypes [15,16], was
also found to influence drug pharmacokinetics on MDR1
genotype-phenotype correlation in further studies [6,20,49].
Haplotypes analysis in this work provided the evidence that
genetic association existed between each other among C1236T,
G2677A/T and C3435T, and haplotypes of MDR1 influenced
tacrolimus concentration/dose (C/D) ratios in liver transplant
recipients. Our findings showed that recipients who carried T-T
haplotype and an additional T/T homozygote at either SNPs
required higher doses, when C1236T and G2677A/T were
combined. The association between haplotypes for G2677A/T
and C3435T and tacrolimus C/D ratio was weak after max(T)
permutation adjustment.
Patients who have received a new liver, with a different genetic
background, will metabolize drugs in different ways. Dose
requirements of tacrolimus would be predicted much more
precisely, if genetic polymorphism of MDR1 is investigated both
in donors and recipients. And several research groups have
obtained some helpful results [25,28,50].
The ultimate goal of human genetics and genomics studies is to
understand the mechanism of gene interaction networks, which
would finally explain how gene-drug interactions work [51]. Based
on these efforts, pharmacologists and physicians hope that the
individualized drug therapy would become reality one day. It is
not difficult to identify genes contributing to some phenotype, such
as drug pharmacokinetics. However, the phenotype is seldom
monogenic. Lots of genes, including downstream molecules, are
implicated in biological regulation. To facilitate the identification
of these genes, new genome-wide research techniques have been
developed. The Affymetrix or Illumina SNP chips are the newest
human GWAS (genome wide association study) methods, which
produce high throughput SNP data from big ethnic populations
with high costs. For instance, by analyzing Affymetrix SNP chips
data of a population suffering SLE (systemic lupus erythematosus),
several susceptibility genes participating in network of immune
response and signal regulation pathway were identified, including
immune complex processing and immune signal transduction in
lymphocytes [52]. However, only large research groups with
enough budgets could afford it. For most research groups, it would
be quite sensible to pick up some candidates from databases, and
investigate in replicate populations followed by mechanism studies.
For those SNPs, which have been proved clinically effective,
genotyping with a cost of less than 1 US dollar for each site could
significantly promote the development of individualized drug
treatment.
In conclusion, our results provided new evidence of the
association of MDR1 and tacrolimus dose requirements, which
could be a great help to the individualized tacrolimus treatment of
liver transplant recipients.
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